Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FCN-159 in Adult NF1-Related Plexiform Neurofibromas
NCT05913037Phase 3Active, not recruiting
- Sponsor
- Fosun Pharma
- Start
- Jun 2023
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in plexiform neurofibroma (PN) comparing FCN-159 with Placebo (2 arms). Primary endpoint: Objective Response Rate evaluated by BIRC at 2 years. Started Jun 2023; status: active, not recruiting.
02
Drugs
luvometinib
03
Conditions
plexiform neurofibroma (PN)
Beyond the preview
Go deeper on NCT05913037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05913037.